Current Report Filing (8-k)
July 29 2021 - 04:09PM
Edgar (US Regulatory)
0001549084Nasdaqfalse00015490842021-07-292021-07-29
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of
1934
July 29, 2021
Date of Report (date of earliest event reported)
Ekso Bionics Holdings, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
|
|
|
Nevada
|
001-37854 |
99-0367049 |
(State or other jurisdiction of incorporation or
organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
|
1414 Harbour Way South, Suite 1201
|
Richmond
|
California
|
94804
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
(510) 984-1761
Registrant's telephone number, including area code
Not Applicable
________________________
(Former name or former address, if changed since last
report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
|
|
|
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock, $0.001 par value per share |
EKSO |
Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act.
o
Item 2.02 Results of Operations and Financial
Condition
On July 29, 2021, Ekso Bionics Holdings, Inc. (the “Company”)
reported its financial results for the quarter ended June 30, 2021.
The full text of the press release announcing such results is
attached as Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated herein by reference.
The information contained in this report, including the information
contained in Exhibit 99.1, is being furnished and shall not be
deemed “filed” for purposes of Section 18 of the Securities and
Exchange Act of 1934, as amended, or incorporated by reference into
any filing of the Company, whether made before or after the date
hereof, regardless of any general incorporation language in such
filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly
authorized.
EKSO BIONICS HOLDINGS, INC.
By: /s/
John F.
Glenn
Name: John F. Glenn
Title: Chief Financial Officer
Dated: July 29, 2021
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2022 to May 2022
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From May 2021 to May 2022